Align Technology announces winner of 2020 Invisalign Ortho Summit Case Shoot-Out
Dr. Keith Sellers selected as the winner out of 4 finalists including Dr. Tarek El-Bialy, Dr. Mike Lanzetta, and Dr. Gregory Ross, by showcasing a complex orthodontic treatment using Invisalign clear aligners at the Invisalign Virtual Ortho Summit
TEMPE, Ariz. -- Align Technology, Inc. (NASDAQ: ALGN) today announced the winner of the 2020 Invisalign Ortho Summit Case Shoot-out, one of the Company’s live case presentations during the virtual Summit. Dr. Keith Sellers of Charlotte, North Carolina received the greatest number of attendee votes for his Class II/Class III Invisalign case presentation. The Invisalign Ortho Summit Case Shoot-out program features Invisalign treatment outcomes submitted by orthodontists from across North America. Doctors with the best treatment outcomes in each of four Summit Case Shoot-out theme categories are invited to present their case at the Invisalign Ortho Summit, with the best or favorite overall case presentation determined by audience voting. The theme categories for the 2020 Invisalign Ortho Summit Case Shoot-out Teen Treatment, Open Bite/Deep Bite Treatment, Invisalign with Mandibular Advancement/Invisalign First Treatment, and Class II/Class III treatment. The 2020 Invisalign Ortho Summit Case Shoot-out voting ran from mid-November 2020 through late January 2021 as part of the first-ever virtual Invisalign Ortho Summit.
“The Invisalign Ortho Summit Case Shoot-out is always one of the most highly anticipated and exciting events during Ortho Summit because it’s both an opportunity to see the wide variety of patients who benefit from Invisalign treatment and peer-to-peer validation for orthodontists who are leveraging the Align digital platform for great clinical experiences and outcomes,” said Simon Beard, Align senior vice president and managing director, Americas. “It is a combination of patient stories together with the examples of how our technology enables doctors to transform smiles and change lives, and we are grateful to orthodontists across North America for sharing their complex clinical cases and to their patients for trusting Invisalign treatment to transform their smiles.”
Dr. Keith Sellers practices orthodontics in Charlotte, North Carolina and is an Invisalign Diamond level provider who has treated more than 2,500 patients with Invisalign clear aligners. His challenging Class II/Class III category treatment featured a 65 year old patient with severe mandibular crowding, flared maxillary and mandibular incisors, severe overjet, recession, and multiple missing teeth. His patient, Vickie, also had an extreme fear of dental treatment.
“Vickie was a joy to treat. Her energy, excitement, and enthusiasm towards Invisalign treatment was palpable. In just over a year of treatment, we were able to transform Vickie’s smile and give her a healthy, beautiful smile that she loves. Not only did we achieve a great clinical outcome, but we were also able to give her a great treatment experience with the Invisalign system that put her fears to rest so that she could have the smile she wants and deserves. I love sharing Vickie’s case because it highlights the kind of life-changing treatment we can accomplish every day with Invisalign treatment in a digital orthodontic practice,” said Dr. Sellers.
The Invisalign Summit Case Shoot-out is part of Align’s Global Invisalign Gallery program (link: https://global.invisaligngallery.com/), which recognizes doctors who have achieved successful clinical outcomes using Invisalign treatment across a broad range of malocclusions. In North America, four treatment categories are defined each year and doctors submit cases for consideration via a blind peer review and voting process. The finalists selected in each treatment category go on to compete in the Invisalign Summit Case Shoot-out, where the favorite case is selected by the Summit audience.
Dr. Sellers competed alongside three other experienced orthodontists, each the finalist in their treatment category: Dr. Tarek El-Bialy of Alberta, Canada (Teen Treatment Category); Dr. Mike Lanzetta of Detroit, Michigan (Open Bite/Deep Bite Treatment Category); and Dr. Gregory Ross of Forest Lake, Minnesota (Invisalign with Mandibular Advancement/Invisalign First Treatment Category).
-
Most popular related searches
Related news
-
Bayer receives positive CHMP opinion for finerenone as a new treatment for adult patients with chronic kidney disease associated with type 2 diabetes
Finerenone, a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is recommended by CHMP for marketing authorization for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) CHMP opinion is based on the results of the Phase III FIDELIO-DKD study investigating the efficacy and safety of finerenone on kidney and cardiovascular outcomes in patients with CKD associated with T2D Final European Commission decision is expected in the coming months The Committee for...
-
Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ARASENS trial demonstrates an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT, a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) / Bayer plans to present these pivotal data at a forthcoming scientific congress and to discuss them with health authorities / ARASENS is part of broad development program for darolutamide which includes another ongoing Phase III trial in mHSPC, ARANOTE,...
-
New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy
Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as seen in the FIDELIO-DKD study Analysis of the FIDELIO-DKD study highlighted that early reduction of urine albumin-to-creatinine ratio (UACR) with finerenone reduced the risk of cardiovascular events and of disease progression of CKD, underpinning the importance of timely...
-
Emerald changes peer review terminology to be more inclusive for all
From September, we`re updating all our author guidelines and journal homepages on our peer review policies. In line with recent updates from fellow publishers, we`ll endeavour to no longer include the term(s) ‘single blind’ or ‘double blind’ in our guidance and will instead use ‘single anonymous’ or ‘double anonymous’. We hope that as well as making our guidelines more inclusive, this will also provide clarity to first-time authors around the process. This is a...
-
Artugen is currently enrolling in C. difficile infection study.
Artugen is currently enrolling subjects in “A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study of ART24 in Subjects Recently Cured of a C. difficileinfection” We are looking for volunteers to participate in a new study to help lower the recurrence rate of C. difficile infections. If you are someone who was diagnosed, treated, and recovered from the infection and are now healthy, you are eligible to enroll. More information
Customer comments
No comments were found for Align Technology announces winner of 2020 Invisalign Ortho Summit Case Shoot-Out. Be the first to comment!